KalshiTechOpenUpdated Jun 10, 2026
Will the FDA approve camizestrant for advanced breast cancer?
3 markets · 1y
✨ Ask about this eventMarkets in this event
Kalshi
Open
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028? — Before Jan 1, 2028
Yes77¢
No23¢
Yes ≈ 77% chance
$91 Vol 0pts1y
Kalshi
Open
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027? — Before Jan 1, 2027
Yes64¢
No36¢
Yes ≈ 64% chance
$505 Vol 0pts5mo
Kalshi
Open
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026? — Before Oct 1, 2026
Yes36¢
No64¢
Yes ≈ 36% chance
$1K Vol 0pts2mo
Data from Kalshi’s public API, for informational purposes only. PredictPal is not affiliated with any platform and does not facilitate trading.
Discussion
optional stance
Loading…